Clinical trials: MYOSITIS
Interstitial Lung Disease, Scleroderma
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
- Trial name
- RECITAL (NCT01862926)
- Testing
- Rituximab, Cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Juvenile Dermatomyositis
Juvenile Dermatomyositis
This is a retrospective descriptive cross-sectional and observational multicenter clinical and progressive study of juvenile dermatomyositis.
- Trial name
- NCT03433638
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Lupus Erthematosus, Sjogren's Syndrome
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an…
- Conditions
- Systemic Lupus Erthematosus, Sjogren's Syndrome, Inflammatory Myopathies, Systemic Sclerosis (SSc)
- Trial name
- NCT07188285
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Dermatomyositis
A Pilot Study of Etanercept in Dermatomyositis
The purpose of the study is to obtain preliminary data regarding the safety and tolerability of etanercept in DM. In addition, we will use the study to assess the variability, reliability, and responsiveness of the core set of…
- Trial name
- NCT00112385
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital
Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age.
- Trial name
- NCT00769860
- Testing
- Arimoclomol
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richard Barohn, MD
Dermatomyositis
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children.
- Trial name
- JADE (NCT06004817)
- Testing
- evaluation of clinical severity
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Central Hospital, Nancy, France
COVID, Sars-CoV2
Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019…
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection, Myositis
- Trial name
- NCT04367350
- Testing
- laboratory biomarkers, muscle ultrasound
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Tuebingen
Osteomyelitis, Septic Arthritis
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
The goal of this study is to figure out the best doses for two antibiotics (called cefadroxil and cephalexin) when they are used to treat bone, joint, or muscle infections in children.
- Conditions
- Osteomyelitis, Septic Arthritis, Pyomyositis
- Trial name
- NCT03802552
- Testing
- Cefadroxil, Cephalexin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Polymyositis, Dermatomyositis
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
- Conditions
- Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis
- Trial name
- NCT02971683
- Testing
- Abatacept subcutaneous
- Where
- 79 sites in United States, Australia and 9 more
- Volunteers
- 149 people
- Sponsor
- Bristol-Myers Squibb
Fibrodysplasia Ossificans Progressiva
A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
This is a three period study design consisting of a 6-month, randomized, double-blind placebo-controlled treatment (period 1) followed by a 6-month, open-label treatment (period 2) and a follow-up treatment period (period 3).
- Trial name
- LUMINA-1 (NCT03188666)
- Testing
- REGN2477
- Where
- 11 sites in United States, Canada and 6 more
- Volunteers
- 44 people
- Sponsor
- Regeneron Pharmaceuticals
Inclusion Body Myositis (IBM)
Natalizumab in Inclusion Body Myositis (IBM)
Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death may be a novel treatment for IBM.
- Trial name
- IBM-NAT (NCT02483845)
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Phoenix Neurological Associates, LTD
Polymyositis, Dermatomyositis
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group.
- Trial name
- NCT07122648
- Testing
- PN-101
- Where
- 5 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Paean Biotechnology Inc.
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
- Trial name
- NCT06479863
- Testing
- Pozelimab/Cemdisiran
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Austin Neuromuscular Center
Inclusion Body Myositis
Molecular Profile of the Evolution of Inclusion Body Myositis
This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject.
- Trial name
- IBM-RNAseq (NCT03299335)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Dermatomyositis, Polymyositis
Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis
The purpose of this study is to evaluate the efficacy of an active rehabilitation program on disability and quality of life of patients affected by dermatomyositis and polymyositis.
- Trial name
- NCT01415219
- Testing
- Active rehabilitation
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Lille
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- NCT07104721
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Dermatomyositis, Adult Type
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.
- Trial name
- NCT05986162
- Testing
- Itolizumab
- Volunteers
- 44 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Pain, Weakness
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
This study will evaluate whether a dietary supplement, coenzyme Q10 (CoQ10), will improve muscle symptoms, such as muscle aches, pains, cramps, and/or weakness, which are experienced by some individuals who use statin medications.
- Conditions
- Pain, Weakness, Cramps, Myalgia or Myositis Nos
- Trial name
- NCT01032993
- Testing
- Coenzyme Q10
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Catherine Buettner
Myositis, Dermatomyositis
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
Background: Dermatomyositis (DM) and juvenile dermatomyositis (JDM) are diseases that weaken the immune system. DM and JDM can affect the muscles, skin, joints, and lungs and cause skin rashes and muscle inflammation.
- Trial name
- NCT07012057
- Testing
- Deucravacitinb
- Where
- United States
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)